risks of glp 1 agonists GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution – The Chicago Council on Science and Technology GLP-1 Agonists in Cardiovascular Diseases:

Less commonly, users report vivid dreams or nightmares

OR: 1.10, 95% CI: 0.961.27, P = 0.185), while also showing a lower risk of high WHtR (OR: 0.85, 95% CI: 0.740.97, P = 0.022)

On July 23-24, 2026, the PCAC voted to recommend BPC-157, KPV, MOTS-c,TB-500, Epitalon and Semax for inclusion on the 503A Bulks List

Quantification of neurotoxin BMAA (-N-methylamino-L-alanine) in seafood from Swedish markets

Temperature monitoring may be advisable in certain situations, particularly for patients living in areas with extreme temperature variations or unreliable climate control

Botanical Oil Blend: A curated selection of plant-derived oils that gently emulsifies to lift away debris while providing essential nutrients to keep the skin soft and supple